Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

被引:15
|
作者
Bardia, Aditya
Krop, Ian
Meric-Bernstam, Funda
Tolcher, Anthony W.
Mukohara, Toru
Lisberg, Aaron
Shimizu, Toshio
Hamilton, Erika
Spira, Alexander I.
Papadopoulos, Kyriakos P.
Greenberg, Jonathan
Gu, Wen
Kobayashi, Fumiaki
Zebger-Gong, Hong
Kawasaki, Yui
Wong, Rie
Kogawa, Takahiro
机构
关键词
D O I
10.1158/1538-7445.SABCS22-P6-10-03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P6-10-03
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
    Spira, A.
    Lisberg, A.
    Sands, J.
    Greenberg, J.
    Phillips, P.
    Guevara, F.
    Tajima, N.
    Kawasaki, Y.
    Gu, J.
    Kobayashi, F.
    Yamamoto, N.
    Johnson, M.
    Meric-Bernstam, F.
    Yoh, K.
    Garon, E.
    Heist, R.
    Shimizu, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S106 - S107
  • [2] Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study
    Shimizu, Toshio
    Lisberg, Aaron E.
    Sands, Jacob M.
    Greenberg, Jonathan
    Phillips, Penny
    Tajima, Naoyuki
    Kawasaki, Yui
    Gu, Jessie
    Kobayashi, Fumiaki
    Yamamoto, Noboru
    Johnson, Melissa
    Meric-Bernstam, Funda
    Yoh, Kiyotaka
    Garon, Edward B.
    Heist, Rebecca S.
    Spira, Alexander
    ANNALS OF ONCOLOGY, 2021, 32 : S285 - S285
  • [3] Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer (BC)
    Meric-Bernstam, Funda
    Krop, Ian
    Juric, Dejan
    Kogawa, Takahiro
    Hamilton, Erika
    Spira, Alexander I.
    Mukohara, Toru
    Tsunoda, Takuya
    Damodaran, Senthil
    Greenberg, Jonathan
    Gu, Wen
    Kobayashi, Fumiaki
    Zebger-Gong, Hong
    Kawasaki, Yui
    Wong, Rie
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2-and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
    Bardia, Aditya
    Krop, Ian E.
    Kogawa, Takahiro
    Juric, Dejan
    Tolcher, Anthony W.
    Hamilton, Erika P.
    Mukohara, Toru
    Lisberg, Aaron
    Shimizu, Toshio
    Spira, Alexander I.
    Tsurutani, Junji
    Damodaran, Senthil
    Papadopoulos, Kyriakos P.
    Greenberg, Jonathan
    Kobayashi, Fumiaki
    Zebger-Gong, Hong
    Wong, Rie
    Kawasaki, Yui
    Nakamura, Tadakatsu
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (19) : 2281 - 2294
  • [5] TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors
    Garon, E.
    Johnson, M.
    Lisberg, A.
    Spira, A.
    Yamamoto, N.
    Heist, R.
    Sands, J.
    Yoh, K.
    Meric-Bernstam, F.
    Kitazono, S.
    Greenberg, J.
    Kobayashi, F.
    Guevara, F.
    Kawasaki, Y.
    Shimizu, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S892 - S893
  • [6] Datopotamab deruxtecan in advanced/metastatic HER2-breast cancer: Results from the phase 1 TROPION-PanTumor01 study
    Krop, Ian
    Juric, Dejan
    Shimizu, Toshio
    Tolcher, Anthony
    Spira, Alexander
    Mukohara, Toru
    Lisberg, Aaron E.
    Kogawa, Takahiro
    Papadopoulos, Kyriakos P.
    Hamilton, Erika
    Damodaran, Senthil
    Greenberg, Jonathan
    Gu, Wen
    Kobayashi, Fumiaki
    Guevara, Ferdinand
    Jikoh, Takahiro
    Kawasaki, Yui
    Meric-Bernstam, Funda
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [7] Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION-PanTumor01 study
    Lisberg, Aaron
    Drakaki, Alexandra
    Meric-Bernstam, Funda
    Alhalabi, Omar
    Kojima, Takahiro
    Kato, Manabu
    Spira, Alexander I.
    Salkeni, Mohamad Adham
    Heist, Rebecca
    Gao, Xin
    Bhave, Manali A.
    Klauss, Gunnar
    Sakaki, Hayato
    Kakurai, Yasuyuki
    Kogawa, Takahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 603 - 603
  • [8] Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): Results from the phase II TROPION-PanTumor03 study
    Oaknin, A.
    Ang, J. E.
    Rha, S. Y.
    Yonemori, K.
    Kristeleit, R.
    Lin, C-C.
    Satoh, T.
    Garcia, P. Estevez
    Sendur, M. A. N.
    Rodriguez, L. Medina
    Italiano, A.
    Lugowska, I.
    Ray-Coquard, I. L.
    Oza, A. M.
    Zhao, J. L.
    Gajavelli, S.
    Filant, J.
    Bodla, S.
    Janjigian, Y. Y.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S547 - S548
  • [9] Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
    Alhalabi, Omar
    Meric-Bernstam, Funda
    Lisberg, Aaron
    Drakaki, Alexandra
    Garmezy, Benjamin
    Kogawa, Takahiro
    Spira, Alexander I.
    Salkeni, Mohamad Adham
    Gao, Xin
    Tolcher, Anthony W.
    Bhave, Manali A.
    Doroshow, Deborah Blythe
    Hoffman-Censits, Jeannie
    Klauss, Gunnar
    Kaga, Yoshiaki
    Kakurai, Yasuyuki
    Kojima, Takahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [10] Japanese subgroup analysis of datopotamab deruxtecan in NSCLC cohort of TROPION-PanTumor01, a phase 1 study
    Shimizu, Toshio
    Kitazono, Satoru
    Garon, Edward B.
    Johnson, Melissa L.
    Lisberg, Aaron
    Spira, Alexander
    Yamamoto, Noboru
    Heist, Rebecca S.
    Sands, Jacob M.
    Meric-Bernstam, Funda
    Zenke, Yoshitaka
    Yanagitani, Noriko
    Greenberg, Jonathan
    Kobayashi, Fumiaki
    Kawasaki, Yui
    Yoh, Kiyotaka
    ANNALS OF ONCOLOGY, 2022, 33 : S476 - S476